Search results for "Matrix tablets"

showing 3 items of 3 documents

Medium-Term Culture of Primary Oral Squamous Cell Carcinoma in a Three-Dimensional Model: Effects on Cell Survival Following Topical 5-Fluororacile D…

2012

Since the activity of several conventional anticancer drugs is restricted by resistance mechanisms and dose-limiting side-effects, the design of formulations for local application on malignant lesions seems to be an efficient and promising drug delivery approach. In this study, the effect of locally applied 5-FU on cell death was evaluated both in a SCC4/HEK001 model and in a newly proposed 3D outgrowth model of oral squamous cell carcinoma (OSCC). Initially, the optimal drug dose was established by delivery of solutions containing different amounts of 5-FU. The solution containing 1% (w/v) of 5-FU resulted effective in inducing cell death with complete eradication of cell colonies. Buccal …

3D OutgrowthSettore BIO/16 - Anatomia UmanaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSettore MED/28 - Malattie Odontostomatologiche3D Outgrowths; OSCC; 5-FU; Matrix tabletsOSCC5-FUMatrix tablets
researchProduct

Bioadhesive Matrix Tablets Loaded with Lipophilic Nanoparticles as Vehicles for Drugs for Periodontitis Treatment: Development and Characterization

2019

Periodontitis treatment is usually focused on the reduction or eradication of periodontal pathogens using antibiotics against anaerobic bacteria, such as metronidazole (MTR). Moreover, recently the correlation between periodontal diseases and overexpression of reactive oxygen species (ROS) led to the introduction of antioxidant biomolecules in therapy. In this work, bioadhesive buccal tablets, consisting of a hydrophilic matrix loaded with metronidazole and lipophilic nanoparticles as a vehicle of curcumin, were developed. Curcumin (CUR)-loaded nanostructured lipid carriers (NLC) were prepared using glycyrrhetic acid, hexadecanol, isopropyl palmitate and Tween&reg

Isopropyl palmitateoral mucosal drug deliveryPolymers and PlasticsBioadhesiveSonicationbuccal matrix tabletsnanostructured lipid carriersbuccal matrix tablet02 engineering and technologynanostructured lipid carrier030226 pharmacology & pharmacyhydrophilic spongeArticlelcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemetronidazolelcsh:Organic chemistryPulmonary surfactantMucoadhesioncurcuminoral diseaseperiodontitisChromatographyChemistryGeneral ChemistryBuccal administrationPermeation021001 nanoscience & nanotechnologySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNLCAnaerobic bacteria0210 nano-technologybuccal delivery
researchProduct

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system

2014

Context: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose. Objective: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system. Materials and Methods: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudrag…

DrugEmodinPolymersSwinemedia_common.quotation_subjectChemistry PharmaceuticalAcrylic ResinsPharmaceutical ScienceDentistryAloinPharmacologyFriabilityPermeabilityBarbaloin buccal tablets aloin matrix tablets oro-mucosal delivery locoregional drug delivery buccal mucosa.chemistry.chemical_compoundDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoverymedicineAnimalsDosingAloemedia_commonPharmacologybusiness.industryOrganic ChemistryMouth MucosaAdhesivenessReproducibility of ResultsPermeationDrug LiberationchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySwellingmedicine.symptombusinessEx vivoTablets
researchProduct